Skip to main content

Cardlytics Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

CDLX$1.63-10.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows (Unaudited)

Six Months EndedJune 30,
20242023
Operating activities
Net Loss$(28,532)$(9,900)
Adjustments to reconcile net loss to net cash used in operating activities:
Credit loss expense3,761744
Depreciation and amortization12,77913,775
Amortization of financing costs charged to interest expense850819
Amortization of right-of-use assets1,0722,205
Gain on debt extinguishment(13,017)—
Stock-based compensation expense23,62919,707
Change in contingent consideration9(23,326)
Other non-cash expense (income), net663(3,147)
Change in operating assets and liabilities:
Accounts receivable14,78318,069
Prepaid expenses and other assets(393)430
Accounts payable810(2,046)
Other accrued expenses(7,253)(10,954)
Partner Share liability(15,114)269
Consumer Incentive liability(7,234)(10,958)
Net cash used in operating activities(13,188)(4,313)
Investing activities
Acquisition of property and equipment(932)(342)
Capitalized software development costs(8,673)(5,207)
Business acquisitions, net of cash acquired202—
Net cash used in investing activities(9,403)(5,549)
Financing activities
Proceeds from issuance of debt—30,000
Settlement of contingent consideration(14,166)(50,050)
Principal payments of the 2018 Line of Credit(30,000)(11)
Principal payments of 2020 Convertible Senior Notes(169,291)—
Proceeds from issuance of 2024 Convertible Senior Notes172,500—
Proceeds from termination of capped calls related to convertible notes115—
Proceeds from issuance of common stock48,63411
Deferred equity issuance costs—(45)
Equity issuance costs(190)—
Debt issuance costs(5,568)—
Net cash provided by (used in) financing activities2,034(20,095)
Effect of exchange rates on cash, cash equivalents and restricted cash(25)117
Net decrease in cash, cash equivalents and restricted cash(20,582)(29,840)
Cash, cash equivalents, and restricted cash — Beginning of period91,830121,985
Cash, cash equivalents, and restricted cash — End of period$71,248$92,145

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Six Months EndedJune 30,
20242023
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:
Cash and cash equivalents$71,248$92,069
Restricted cash—76
Total cash, cash equivalents and restricted cash — End of period$71,248$92,145
Supplemental disclosure of cash flow information:
Cash paid for interest$2,202$1,924
Amounts accrued for property and equipment$378$—
Amounts accrued for capitalized software development costs$150$—
Issuance of common stock, net of issuance costs - Settlement Agreement (as defined below)$27,451$—
Amounts accrued for debt issuance costs$354$—
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.